Skye Bioscience, Inc.: 10-K filed 2023-03-31

Name: Skye Bioscience, Inc.: 10-K filed 2023-03-31
Creator: Skye Bioscience, Inc.

What Skye Bioscience, Inc. reported in its annual report filed 2023-03-31 (fiscal FY 2022): 37 published measures, 76 facts as tagged in accession 0001516551-23-000038.

This filing

Form: 10-K (annual report)
Filed: 2023-03-31
Fiscal period: fiscal FY 2022
Accession: 0001516551-23-000038 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Skye Bioscience, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-12-31	9,111,072	USD
At 2021-12-31	9,855,088	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-12-31	12,119,126	USD
At 2021-12-31	3,990,922	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-12-31	-3,008,054	USD
At 2021-12-31	5,864,166	USD
At 2020-12-31	450,786	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-19,481,602	USD	365
2021-01-01 to 2021-12-31	-8,522,182	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-12,744,072	USD	365
2021-01-01 to 2021-12-31	-6,474,888	USD	365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	28,060	USD	365
2021-01-01 to 2021-12-31	90,866	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-208,794	USD	365
2021-01-01 to 2021-12-31	13,079,356	USD	365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	5,214,395	USD	365
2021-01-01 to 2021-12-31	-90,866	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-12-31	-66,737,765	USD
At 2021-12-31	-47,256,163	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	555,270,089	shares	365
2021-01-01 to 2021-12-31	406,599,390	shares	365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	555,270,089	shares	365
2021-01-01 to 2021-12-31	406,599,390	shares	365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-0.04	USD/shares	365
2021-01-01 to 2021-12-31	-0.02	USD/shares	365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-0.04	USD/shares	365
2021-01-01 to 2021-12-31	-0.02	USD/shares	365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	6,741	USD	365
2021-01-01 to 2021-12-31	2,100	USD	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2022-12-31	87,854	USD
At 2021-12-31	87,710	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	629,032	USD	365
2021-01-01 to 2021-12-31	869,206	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-18,311,732	USD	365
2021-01-01 to 2021-12-31	-7,847,714	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-12-31	8,943,718	USD
At 2021-12-31	9,612,097	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	665,133	USD	365
2021-01-01 to 2021-12-31	769,159	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-12-31	12,119,126	USD
At 2021-12-31	3,912,222	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2022-12-31	1,669,997	USD
At 2021-12-31	897,880	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	18,311,732	USD	365
2021-01-01 to 2021-12-31	7,847,714	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	6,011,805	USD	365
2021-01-01 to 2021-12-31	2,931,437	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-12-31	913,528,958	shares
At 2021-12-31	476,108,445	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2022-12-31	1,249,107	USD
At 2021-12-31	8,987,578	USD
At 2020-12-31	2,473,976	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2022-12-31	71,191	USD
At 2021-12-31	146,972	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2022-12-31	78,700	USD
At 2021-12-31	161,072	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2022-12-31	8,309	USD
At 2021-12-31	8,309	USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2022-12-31	14,984	USD
At 2021-12-31	133,730	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-19,474,861	USD	365
2021-01-01 to 2021-12-31	-8,520,082	USD	365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-19,481,602	USD	365
2021-01-01 to 2021-12-31	-8,522,182	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	6,094,617	USD	365
2021-01-01 to 2021-12-31	4,916,277	USD	365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	114,998	USD	365
2021-01-01 to 2021-12-31	34,131	USD	365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-1,163,129	USD	365
2021-01-01 to 2021-12-31	-672,368	USD	365

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	6,741	USD	365
2021-01-01 to 2021-12-31	2,100	USD	365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	333,547	USD	365
2021-01-01 to 2021-12-31	44,087	USD	365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	0	USD	365
2021-01-01 to 2021-12-31	6,062,774	USD	365

Inspect the source

Entity: Skye Bioscience, Inc. / CIK 0001516551
Captured: 2026-09-20T09:13:51.237Z
SEC response SHA-256: fd229875bbe9efbf8ce715b00820b845a594b6e60bad8dd4ff739bde7e7cfc9e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001516551.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))